SREBF2 and cancer: Furthermore, the sensitization effect was fluvastatin-specific as SREBP2 knockdown did not sensitize lung and breast cancer cells to the anti-cancer effects of doxorubicin, an anti-cancer drug with a distinct mechanism of action compared to fluvastatin (Figure 5B).